Abstract SS02-02: Chemoprevention: Poised for Success

Phase III trials demonstrated that chemoprevention was effective in reducing the risk of breast, prostate, and colorectal cancers, warranting significant research investment and education on its benefits. The FDA approved raloxifene in 2007 to reduce breast cancer risk in high-risk post-menopausal women, adding to the previously approved tamoxifen. The Prostate Cancer Prevention Trial found that finasteride reduced prostate cancer risk by 25% over 7 years, with further studies suggesting it did not cause high-grade cancers. Additionally, a combination of DFMO and sulindac prevented 70% of colon polyps, including 92% of advanced adenomas. These trials highlighted the potential of chemoprevention in significantly reducing common cancer risks, advocating for expanded research and public-private partnerships to advance this field.